⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Carlotta Antoniotti Alessandra Boccaccino Robert S. Seitz Mirella Giordano Aurélie Catteau Daniele Rossini Filippo Pietrantonio Lisa Salvatore Kimberly McGregor Francesca Bergamo Veronica Conca Simone Leonetti Federica Morano Giorgio Papiani Emiliano Tamburini Maria Bensi Sabina Murgioni Douglas Teller Ross Alessandro Passardi Isabelle Boquet Tyler J. Nielsen Jérôme Galon Matthew G. Varga Brock L. Schweitzer Chiara Cremolini

View at Publisher

Ask AI

Bookmark

Share

Abstract

Consort diagram of the study. Control arm indicates FOLFOXIRI plus bevacizumab. Atezo arm indicates FOLFOXIRI plus bevacizumab and atezolizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Antoniotti et al. (2024) studied this question.

synapsesocial.com/papers/68e587eeb6db643587523e41 https://doi.org/10.1158/1078-0432.27030784

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024
2Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024
3Supplementary Figure S2 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024
4Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024
5Supplementary Figure S3 from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024

Data from An immune-related gene expression signature predicts benefit from adding atezolizumab to FOLFOXIRI plus bevacizumab in metastatic colorectal cancer2024
Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024
Supplementary Figure S7 from A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer2024